Symptomatic heart failure, a serious adverse effect of trastuzumab, occursin 1% to 4% of patients treated with the antibody, whereas left ventricular ejection fraction declines substantially in 10% of patients. Trastuzumab, a drug targeting human epidermal growth factor receptor 2, improves survival rate in women with metastatic breast cancer. Successful use of trastuzumab with anthracyclinebased. Tener una fevi basal con ecografia 3 d idealmente o ecografia 2 d. Nov 29, 2011 trastuzumab is regarded as the foundation of care for her2positive breast cancer as it has revolutionized the treatment of this disease across all settings. Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 her2, also called erbb2. Bevacizumab y trastuzumab son dos anticuerpos monoclonales. Trastuzumab may significantly improve survival among women with advanced breast cancer, but there are concerns about cardiotoxicity associated with this targeted therapy. Although generally well tolerated, patients may develop symptomatic or asymptomatic cardiotoxicity, forcing a discontinuation of treatment, therefore preventing patients from benefiting from maximal disease control. In four of the five studies, trastuzumab followed anthracycline administration, and prospective cardiac function monitoring was included in all of the trials. For the 15 to 20 percent of patients with breast cancer whose tumors overexpress her2, trastuzumab therapy is important in the treatment of both early and advanced disease.
Management of cardiac health in trastuzumabtreated patients. Patients receive trastuzumab herceptin iv over 6090 minutes on day 1. Mar 27, 2017 trastuzumab is a therapy that targets her2, a protein which is overexpressed in 1525% of breast cancers. Nov 20, 2012 trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor tyrosine kinase her2erbb2. Patients receive trastuzumab as in arm i and oral tamoxifen once daily on days 121. Its use, however, results in a small to modest risk. Pdf cardiotoxicidad reversible en una mujer con 54 anos. Trastuzumabe herceptin, zedora biossimilar apresentacao. Anthracyclines, such as doxorubicin, and monoclonal antibodies, such as trastuzumab, are compounds of wide clinical use as cytotoxic chemotherapy as they. Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 her2, also known as erbb2, has led to a significant breakthrough in the treatment of breast cancer that overexpresses her2 receptors up to 30% of all breast cancer cases, a variant of the disease generally associated with a poor prognosis. The incidence rates were % when the antibody was administered in combination with paclitaxel and 27% when it was administered with an anthracycline. Cardiotoxicidad por quimioterapia pdf download citation on researchgate on dec 1, edwin arevalo guerrero and others published rol del strain miocardico en.
In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cardiotoxicity associated with trastuzumab treatment of her2. Cardiotoxicidad por antraciclicos berenice vicente. Quizlet flashcards, activities and games help you improve your grades. Although adjuvant trastuzumab improves survival in patients with her2positive early breast cancer, there is growing concern about the longterm effect of trastuzumab induced. Cardiotoxicity profile of trastuzumab springerlink. Jul 08, 2011 trastuzumab trz is a monoclonal antibody against the human epidermal growth factor receptor 2 that is found to be overexpressed in 25% to 30% of breast cancer patients.
To our knowledge, this is the first report of trastuzumab induced hepatotoxicity requiring discontinuation of the drug. Ochoa, mauricio escobar, belisario arango, maria h. In spite of the therapeutic benefits of trz, cardiotoxic side effects are still an issue. Cardiotoxicidade associada a terapeutica oncologica. A retrospective study of possible risk and protective factors, abstract objective. Assistant professor of medicine department of breast medical oncology. Trastuzumab 440 mg20 ml en ampula oncologia info medicamento. Trastuzumabinduced cardiotoxicity in early breast cancer. Liver enzyme levels must be closely monitored in patients receiving trastuzumab. Concern about cardiac safety influenced the design of trials evaluating trastuzumab in early breast cancer. Cardiotoxicity of trastuzumab given for 12 months compared. Rt is known to reduce the risk of lrr, meaning the reappearance of the cancer in and around the original site of disease. Trastuzumab with or without tamoxifen in treating women with.
522 845 958 775 69 939 1443 501 45 470 319 1252 280 1283 1111 569 593 384 427 1272 857 136 1281 655 1392 918 1429 962 572 571 40 1331 45 1428 922 1275 1001 575 349 532